Eric Ostertag - Sep 13, 2021 Form 4 Insider Report for Poseida Therapeutics, Inc. (PSTX)

Role
Chief Executive Officer, Director, 10%+ Owner
Signature
/s/ Harry J. Leonhardt, Attorney-in-Fact
Stock symbol
PSTX
Transactions as of
Sep 13, 2021
Transactions value $
$10,017
Form type
4
Date filed
9/15/2021, 06:58 PM
Previous filing
Sep 3, 2021
Next filing
Sep 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PSTX Common Stock Options Exercise $3.23K +2.76K +0.42% $1.17 657K Sep 13, 2021 Direct
transaction PSTX Common Stock Options Exercise $169K +18.5K +2.82% $9.15 675K Sep 13, 2021 Direct
transaction PSTX Common Stock Sale -$163K -20K -9.97% $8.14 181K Sep 14, 2021 See footnote F1, F2, F3
holding PSTX Common Stock 3.68M Sep 13, 2021 See footnote F4
holding PSTX Common Stock 3.38M Sep 13, 2021 See footnote F5
holding PSTX Common Stock 629K Sep 13, 2021 See footnote F6
holding PSTX Common Stock 961K Sep 13, 2021 See footnote F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PSTX Employee Stock Option (Right to Buy) Options Exercise $0 -2.76K -100% $0.00* 0 Sep 13, 2021 Common Stock 2.76K $1.17 Direct F8
transaction PSTX Employee Stock Option (Right to Buy) Options Exercise $0 -18.5K -2.38% $0.00 760K Sep 13, 2021 Common Stock 18.5K $9.15 Direct F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected by Transposagen Biopharmaceuticals, Inc. ("Transposagen") pursuant to a Rule 10b5-1 trading plan established independently of Dr. Ostertag and in connection with a planned dissolution of Transposagen. Dr. Ostertag reports beneficial ownership of the shares held by Transposagen as a result of his affiliation with that entity.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.00 to $8.32 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The shares are held in the name of Transposagen Biopharmaceuticals, Inc., of which Dr. Ostertag is a majority stockholder.
F4 The shares are held in the name of the Eric Ostertag Living Trust dated March 30, 2016, of which the reporting person is the sole trustee.
F5 The shares are held in the name of Titan, LLC, which is owned by the Ostertag Descendents' Trust, of which the reporting person's minor daughter is the sole beneficiary. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F6 The shares are held in the name of Twin Prime Investments, an entity wholly owned by the reporting person.
F7 The shares are held in the name of the Ostertag Family Trust dated March 30, 2016, of which the reporting person is a trustee.
F8 The stock option is fully vested and exercisable.
F9 12.5% of the shares originally subject to the stock option vested and became exercisable on the August 4, 2021, and the remaining shares vest in 42 equal monthly installments thereafter.